-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
As the 200-day countdown to the 4th China International Import Expo, Sanofi, the world's leading multinational biopharmaceutical company, officially announced yesterday that it will participate in the 4th China International Import Expo
.
Upholding solid confidence in the Chinese market and unchanging commitments, Sanofi will bring a series of breakthrough innovative products and medical solutions to the medical equipment and healthcare exhibition area for the fourth time this year, further interpreting the concept of "innovation driving a healthy future"
"As the first batch of multinational pharmaceutical companies to participate in the CIIE, Sanofi has witnessed the vigorous development of the CIIE in the past three years and has fully benefited from the spillover effect of the CIIE", Sanofi Pius S.
Hornstein, PhD, President of China, said, “Participating in the CIIE for 4 consecutive years is Sanofi’s firm commitment to deepening the Chinese market
.
We look forward to using this important platform again to strengthen our cooperation with all parties.
Leverage the "spillover effect" of the Expo to accelerate the implementation of innovation results
Through the past three CIIEs, Sanofi has brought a variety of global innovative products and cutting-edge medical solutions to China
.
Thanks to the continuously expanding "Jinbo effect", these innovations are benefiting more and more Chinese patients
In addition, in the context of accelerating global vaccine innovation, Sanofi Pasteur and the Shenzhen Municipal Government signed a Sino-French vaccine innovation strategic cooperation memorandum during the second CIIE in 2019
.
In September 2020, the first Greater Bay Area Vaccine Summit was successfully held in Shenzhen, becoming a bridge between China and the world for international cooperation and exchanges in vaccine innovation
Full of confidence in China, continue to increase strategic investment
As the first batch of multinational pharmaceutical and health companies to enter China, Sanofi has been deeply involved in the Chinese market for nearly 40 years, always upholding its commitment to "root China and serve China", continue to increase its R&D and production investment in China and gradually have a landing effect
.
In 2020, Sanofi will invest 200 million yuan in the Beijing production base to expand the insulin glargine product line.
After the production line is upgraded and strengthened, it will effectively alleviate the insulin medication demand of the vast majority of diabetic patients in China, and help patients obtain better and safer blood sugar control and better health.
High quality of life
.
In April 2021, Sanofi's first global research institute in China established in the Suzhou Free Trade Zone was also officially put into use
.
This research institute is the fourth global research institute established by Sanofi and the first global research institute in China.
